Recent Advances in the Search for the -Opioidergic System
暂无分享,去创建一个
[1] I. Sora,et al. Antagonistic property of buprenorphine for putative ϵ-opioid receptor-mediated G-protein activation by β-endorphin in pons/medulla of the μ-opioid receptor knockout mouse , 2002, Neuroscience.
[2] L. Tseng. The antinociceptive properties of endomorphin-1 and endomorphin-2 in the mouse. , 2002, Japanese journal of pharmacology.
[3] K. Murayama,et al. Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse. , 2001, European journal of pharmacology.
[4] M. Narita,et al. Partial agonistic action of endomorphins in the mouse spinal cord , 2001, Neuroscience Letters.
[5] J. Kampine,et al. Differential antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse. , 2001, The Journal of pharmacology and experimental therapeutics.
[6] M. Narita,et al. Lack of the involvement of μ1-opioid receptor subtype on motivational effects induced by the endogenous μ-opioid receptor ligands endomorphin-1 and -2 in the mouse , 2001, Neuroscience Letters.
[7] M. Narita,et al. Different motivational effects induced by the endogenous μ-opioid receptor ligands endomorphin-1 and -2 in the mouse , 2001, Neuroscience.
[8] G. Pasternak. Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. , 2001, Life sciences.
[9] G. Pasternak. Incomplete cross tolerance and multiple mu opioid peptide receptors. , 2001, Trends in pharmacological sciences.
[10] M. Narita,et al. Activation of G-proteins in the mouse pons/medulla by β-endorphin is mediated by the stimulation of μ- and putative ε-receptors , 2000 .
[11] K. Murayama,et al. Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone , 2000, Brain Research.
[12] M. Narita,et al. Differential involvement of μ1-opioid receptors in endomorphin- and β-endorphin-induced G-protein activation in the mouse pons/medulla , 2000, Neuroscience.
[13] M. Ohsawa,et al. Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse. , 2000, The Journal of pharmacology and experimental therapeutics.
[14] N. Dun,et al. G protein activation by endomorphins in the mouse periaqueductal gray matter. , 2000, Journal of biomedical science.
[15] J. Kampine,et al. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. , 2000, The Journal of pharmacology and experimental therapeutics.
[16] G. Pasternak,et al. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR‐1F , 2000, FEBS letters.
[17] M. Szikszay,et al. Antinociceptive effects of intrathecal endomorphin-1 and -2 in rats. , 1999, Life Science.
[18] G. Pasternak,et al. Antagonism of heroin and morphine self-administration in rats by the morphine-6beta-glucuronide antagonist 3-O-methylnaltrexone. , 1999, European journal of pharmacology.
[19] P. Sánchez-Blázquez,et al. Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice. , 1999, The Journal of pharmacology and experimental therapeutics.
[20] I. Sora,et al. The μ-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in μ-opioid receptor knockout mice , 1999, Neuroscience.
[21] G. Pasternak,et al. Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. , 1999, Molecular pharmacology.
[22] H. Ueda,et al. Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. , 1999, European journal of pharmacology.
[23] A. Kastin,et al. Differential distribution of endomorphin 1‐ and endomorphin 2‐like immunoreactivities in the CNS of the rodent , 1999 .
[24] R. Przewłocki,et al. Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. , 1999, European journal of pharmacology.
[25] G. Pasternak,et al. Retention of heroin and morphine–6β–glucuronide analgesia in a new line of mice lacking exon 1 of MOR–1 , 1999, Nature Neuroscience.
[26] I. Sora,et al. Absence of G‐protein activation by μ‐opioid receptor agonists in the spinal cord of μ‐opioid receptor knockout mice , 1999, British journal of pharmacology.
[27] A. Kastin,et al. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers , 1998, Peptides.
[28] G. Pasternak,et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. , 1998, The Journal of pharmacology and experimental therapeutics.
[29] H. Akil,et al. Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. , 1998, The Journal of pharmacology and experimental therapeutics.
[30] M. Narita,et al. Characterization of endomorphin-1 and -2 on [35S]GTPgammaS binding in the mouse spinal cord. , 1998, European journal of pharmacology.
[31] A. Kastin,et al. Endomorphin 1 and 2 Have Vasodepressor Activity in the Anesthetized Mouse , 1998, Peptides.
[32] S. Schulz,et al. Immunofluorescent identification of endomorphin‐2‐containing nerve fibers and terminals in the rat brain and spinal cord , 1998, Neuroreport.
[33] A. Cavalli,et al. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. , 1998, Brain research. Molecular brain research.
[34] A. Herz. Opioid reward mechanisms: a key role in drug abuse? , 1998, Canadian journal of physiology and pharmacology.
[35] M. Wessendorf,et al. Immunoreactivity for endomorphin‐2 occurs in primary afferents in rats and monkey , 1998, Neuroreport.
[36] A. Kastin,et al. Localization of Endomorphin-2-Like Immunoreactivity in the Rat Medulla and Spinal Cord , 1997, Peptides.
[37] A. Kastin,et al. Isolation of Relatively Large Amounts of Endomorphin-1 and Endomorphin-2 From Human Brain Cortex , 1997, Peptides.
[38] L. Stone,et al. Spinal analgesic actions of the new endogenous opioid peptides endomorphin‐1 and ‐2 , 1997, Neuroreport.
[39] J. Li,et al. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. , 1997, The Journal of pharmacology and experimental therapeutics.
[40] L. Leventhal,et al. 3‐Methoxynaltrexone, a selective heroin/morphine‐6β‐glucuronide antagonist , 1997, FEBS letters.
[41] A. Kastin,et al. A potent and selective endogenous agonist for the µ-opiate receptor , 1997, Nature.
[42] D. Selley,et al. Acute and Chronic Effects of Opioids on δ and μ Receptor Activation of G Proteins in NG108‐15 and SK‐N‐SH Cell Membranes , 1997 .
[43] L. Tseng,et al. Inhibition of spinal nitric oxide synthase by N ω -nitro-l-arginine blocks the release of met-enkephalin and antinociception induced by supraspinally administered β-endorphin in the rat , 1997, Neuroscience.
[44] I. Sora,et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] E. Nestler,et al. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment , 1997, Brain Research.
[46] Brigitte L. Kieffer,et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.
[47] F. Oehme. Goodman and Gilman 's: The pharmacological basis of therapeutics , 1996 .
[48] D. Selley,et al. Effects of chronic morphine administration on mu opioid receptor- stimulated [35S]GTPgammaS autoradiography in rat brain , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[49] G. Pasternak,et al. Antisense mapping the MOR‐1 opioid receptor: evidence for alternative splicing and a novel morphine‐6β‐glucuronide receptor , 1995, FEBS letters.
[50] J. Traynor,et al. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. , 1995, Molecular pharmacology.
[51] M. Misawa,et al. Blockade of morphine reward through the activation of κ-opioid receptors in mice , 1993, Neuropharmacology.
[52] L. Tseng,et al. Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse. , 1993, The Journal of pharmacology and experimental therapeutics.
[53] Lei Yu,et al. Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.
[54] L. Tseng,et al. Different mechanisms mediating tail-flick inhibition induced by beta-endorphin, DAMGO and morphine from ROb and GiA in anesthetized rats. , 1991, The Journal of pharmacology and experimental therapeutics.
[55] L. Tseng,et al. Different mechanisms mediate beta-endorphin- and morphine-induced inhibition of the tail-flick response in rats. , 1990, The Journal of pharmacology and experimental therapeutics.
[56] G. Pasternak,et al. Naloxonazine actions in vivo. , 1986, European journal of pharmacology.
[57] G. Pasternak,et al. Minireview: Multiple MU opiate receptors , 1986 .
[58] M. Morgan,et al. Analgesic, locomotor and lethal effects of morphine in the mouse: Strain comparisons , 1985, Brain Research.
[59] R. Goodman,et al. Autoradiographic distribution of Mu1 and Mu2 opioid binding in the mouse central nervous system , 1985, Brain Research.
[60] R. Goodman,et al. Autoradiographic analysis of mu1, mu2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice , 1985, Brain Research.
[61] G. Pasternak,et al. Visualization of mu1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[62] G. Pasternak,et al. Classification of multiple morphine and enkephalin binding sites in the central nervous system. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[63] C. Schuster,et al. An analysis of drug-seeking behavior in animals , 1981, Neuroscience & Biobehavioral Reviews.
[64] S. Snyder,et al. Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. , 1981, Science.
[65] L. Hood,et al. Dynorphin-(1-13), an extraordinarily potent opioid peptide. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[66] Choh Hao Li,et al. β-Endorphin as a potent analgesic by intravenous injection , 1976, Nature.
[67] H. Morris,et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity , 1975, Nature.
[68] T. Shippenberg,et al. Evidence that the aversive effects of opioid antagonists and κ-agonists are centrally mediated , 2004, Psychopharmacology.
[69] M. Narita,et al. Evidence for the Existence of the β-Endorphin-Sensitive “ε-Opioid Receptor” in the Brain: The Mechanisms of ε-Mediated Antinociception , 1998 .
[70] D. Selley,et al. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.
[71] T. Reisine. Opioid analgesics and antagonists , 1996 .
[72] L. Recht,et al. Biochemical characterization of high-affinity 3H-opioid binding. Further evidence for Mu1 sites. , 1984, Molecular pharmacology.